Exact Sciences vs Guardant Health

Exact Sciences and Guardant Health are both players in the fast-growing field of precision medicine, utilizing innovative technologies to detect and treat diseases such as cancer. Exact Sciences is known for its flagship product, Cologuard, a noninvasive screening test for colorectal cancer, while Guardant Health offers liquid biopsy tests to identify cancer mutations. Both companies have seen impressive growth in recent years, but their stocks have exhibited different performances. This analysis will compare and contrast Exact Sciences and Guardant Health stocks to help investors make informed decisions.

Exact Sciences or Guardant Health?

When comparing Exact Sciences and Guardant Health, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Exact Sciences and Guardant Health.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Exact Sciences has a dividend yield of -%, while Guardant Health has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Exact Sciences reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Guardant Health reports a 5-year dividend growth of 0.00% year and a payout ratio of -4.32%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Exact Sciences P/E ratio at -73.67 and Guardant Health's P/E ratio at -5.38. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Exact Sciences P/B ratio is 4.04 while Guardant Health's P/B ratio is -1636.68.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Exact Sciences has seen a 5-year revenue growth of 2.73%, while Guardant Health's is 0.69%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Exact Sciences's ROE at -5.56% and Guardant Health's ROE at -432.71%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $69.31 for Exact Sciences and $21.18 for Guardant Health. Over the past year, Exact Sciences's prices ranged from $40.62 to $79.62, with a yearly change of 96.01%. Guardant Health's prices fluctuated between $15.81 and $37.04, with a yearly change of 134.28%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.